Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men
暂无分享,去创建一个
I. U. Haq | I. Haq | L. Ramsay | P R Jackson | P. Jackson | E. Wallis | I U Haq | L E Ramsay | W W Yeo | E J Wallis | W. W. Yeo | P. Jackson
[1] L. Ramsay,et al. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table , 1996, The Lancet.
[2] L. Ramsay,et al. Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence? , 1996, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[3] W. Kannel,et al. Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico. , 1974, Journal of chronic diseases.
[4] K. Anderson,et al. Cardiovascular disease risk profiles. , 1991, American heart journal.
[5] S. Cobbe. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. , 1997, The American journal of cardiology.
[6] J. Robson. Information needed to decide about cardiovascular treatment in primary care , 1997, BMJ.
[7] A. Keys,et al. Probability of Middle‐Aged Men Developing Coronary Heart Disease in Five Years , 1972, Circulation.
[8] M. Abrahamowicz,et al. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study , 1995, BMJ.
[9] H. Tunstall-Pedoe,et al. UK HEART DISEASE PREVENTION PROJECT: INCIDENCE AND MORTALITY RESULTS , 1983, The Lancet.
[10] L. Ramsay,et al. Lipid-lowering for prevention of coronary heart disease: what policy now? , 1996, Clinical science.
[11] B. Swinburn. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. , 1996, The New Zealand medical journal.
[12] H Tunstall-Pedoe,et al. The Dundee coronary risk-disk for management of change in risk factors. , 1991, BMJ.
[13] H. Blackburn,et al. The 7 countries study: 2289 deaths in 15 years , 1984 .
[14] D. Wood,et al. Using a Coronary Risk Score for Screening and Intervention in General Practice , 1996, Journal of cardiovascular risk.
[15] S. Pocock,et al. Identifying men at high risk of heart attacks: strategy for use in general practice. , 1986, British medical journal.
[16] H. Blackburn,et al. The seven countries study: 2,289 deaths in 15 years. , 1984, Preventive medicine.
[17] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[18] M. Burr. Weight and mortality in Whitehall study. , 1982, British medical journal.
[19] L. Coupal,et al. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? , 1995, JAMA.
[20] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[21] W. Kannel,et al. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. , 1987, Journal of chronic diseases.
[22] Statens Beredning för Utvärdering av Medicinsk Metodik. Moderately elevated blood pressure. A report from SBU, the Swedish Council on Technology Assessment in Health Care. , 1995, Journal of internal medicine. Supplement.
[23] Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. The pooling project research group. , 1978, Journal of chronic diseases.
[24] D. Sackett,et al. The number needed to treat: a clinically useful measure of treatment effect , 1995, BMJ.
[25] P. Poole‐Wilson,et al. Prevention of coronary heart disease in clinical practice , 1994 .
[26] A J Dobson,et al. On the use of a logistic risk score in predicting risk of coronary heart disease. , 1990, Statistics in medicine.
[27] L. Ramsay,et al. The Sheffield table for primary prevention of coronary heart disease: corrected , 1996, The Lancet.
[28] H. Tunstall-Pedoe,et al. Belgian Heart Disease Prevention Project: Incidence and mortality results , 1983 .
[29] I. U. Haq,et al. Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease , 1995, The Lancet.
[30] B Cazelles,et al. Estimation of CHD risk in a French working population using a modified Framingham model. The PCV-METRA Group. , 1994, Journal of clinical epidemiology.
[31] R. Brand,et al. Multivariate Prediction of Coronary Heart Disease in the Western Collaborative Group Study Compared to the Findings of the Framingham Study , 1976, Circulation.
[32] P Barham,et al. Management of raised blood pressure in New Zealand: a discussion document. , 1993, BMJ.
[33] P. Poole‐Wilson,et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. , 1994, European heart journal.